These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26297673)

  • 1. Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities.
    Bernardo I; Bozinovski S; Vlahos R
    Pharmacol Ther; 2015 Nov; 155():60-79. PubMed ID: 26297673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.
    Brassington K; Selemidis S; Bozinovski S; Vlahos R
    Clin Sci (Lond); 2019 Apr; 133(7):885-904. PubMed ID: 30979844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidities of chronic obstructive pulmonary disease.
    Corsonello A; Antonelli Incalzi R; Pistelli R; Pedone C; Bustacchini S; Lattanzio F
    Curr Opin Pulm Med; 2011 Dec; 17 Suppl 1():S21-8. PubMed ID: 22209926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of comorbidities in COPD patients by disease severity in a German population.
    Greulich T; Weist BJD; Koczulla AR; Janciauskiene S; Klemmer A; Lux W; Alter P; Vogelmeier CF
    Respir Med; 2017 Nov; 132():132-138. PubMed ID: 29229085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical murine models of Chronic Obstructive Pulmonary Disease.
    Vlahos R; Bozinovski S
    Eur J Pharmacol; 2015 Jul; 759():265-71. PubMed ID: 25818750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy.
    Kirkham P; Rahman I
    Pharmacol Ther; 2006 Aug; 111(2):476-94. PubMed ID: 16458359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease).
    Hansen MJ; Gualano RC; Bozinovski S; Vlahos R; Anderson GP
    Pharmacol Ther; 2006 Jan; 109(1-2):162-72. PubMed ID: 16154635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidity in chronic obstructive pulmonary disease.
    Negewo NA; McDonald VM; Gibson PG
    Respir Investig; 2015 Nov; 53(6):249-58. PubMed ID: 26521102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries.
    Takahashi S; Betsuyaku T
    Respir Investig; 2015 Nov; 53(6):259-70. PubMed ID: 26521103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic manifestations and comorbidities of COPD.
    Barnes PJ; Celli BR
    Eur Respir J; 2009 May; 33(5):1165-85. PubMed ID: 19407051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress and free radicals in COPD--implications and relevance for treatment.
    Domej W; Oettl K; Renner W
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1207-24. PubMed ID: 25378921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: antioxidant therapeutic targets.
    Rahman I
    Curr Drug Targets Inflamm Allergy; 2002 Sep; 1(3):291-315. PubMed ID: 14561194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease.
    Passey SL; Hansen MJ; Bozinovski S; McDonald CF; Holland AE; Vlahos R
    Pharmacol Ther; 2016 Oct; 166():56-70. PubMed ID: 27373503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comorbidities with COPD].
    Hashimoto S; Gon Y; Mizumura K
    Nihon Rinsho; 2016 May; 74(5):850-7. PubMed ID: 27254958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular dysfunction in chronic obstructive pulmonary disease: current evidence and perspectives.
    Clarenbach CF; Thurnheer R; Kohler M
    Expert Rev Respir Med; 2012 Feb; 6(1):37-43. PubMed ID: 22283577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease.
    Corlateanu A; Covantev S; Mathioudakis AG; Botnaru V; Siafakas N
    Respir Investig; 2016 Nov; 54(6):387-396. PubMed ID: 27886849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic obstructive pulmonary disease and cardiovascular system].
    Gürgün A; Gürgün C
    Tuberk Toraks; 2008; 56(4):464-71. PubMed ID: 19123087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROS in the local and systemic pathogenesis of COPD.
    Langen RC; Korn SH; Wouters EF
    Free Radic Biol Med; 2003 Aug; 35(3):226-35. PubMed ID: 12885585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation pathway and exacerbations in COPD: the role of NAC.
    Matera MG; Calzetta L; Cazzola M
    Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy.
    MacNee W
    Novartis Found Symp; 2001; 234():169-85; discussion 185-8. PubMed ID: 11199095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.